Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-08-16
2005-08-16
Nolan, Patrick J. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C514S013800
Reexamination Certificate
active
06929796
ABSTRACT:
Isolated and purified peptides and variants thereof, useful to prevent or treat antibody-mediated diseases, or indications caused by an undesirable antibody response to a given antigen, are provided. Also provided are peptides and methods useful to prevent or treat indications associated with the use of viral vectors in gene replacement therapy. Further, a method to inhibit or prevent aberrant immune responses to exogenous, non-infectious antigen is provided.
REFERENCES:
patent: 4649132 (1987-03-01), Zimmerman et al.
patent: 4822606 (1989-04-01), Snyderman et al.
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 5114721 (1992-05-01), Cohen et al.
patent: 5158884 (1992-10-01), Conti-Tronconi et al.
patent: 5298490 (1994-03-01), Heavner et al.
patent: 5571499 (1996-11-01), Hafler et al.
patent: 5571500 (1996-11-01), Hafler et al.
patent: 5578496 (1996-11-01), Atassi et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5614396 (1997-03-01), Bradley et al.
patent: 5641473 (1997-06-01), Hafler et al.
patent: 5641474 (1997-06-01), Hafler et al.
patent: 5681571 (1997-10-01), Holmgren et al.
patent: 5785973 (1998-07-01), Bixler et al.
patent: 5817308 (1998-10-01), Scott et al.
patent: 6077509 (2000-06-01), Weiner et al.
patent: 6106844 (2000-08-01), King
patent: 6268491 (2001-07-01), Garman et al.
patent: 0378881 (1989-01-01), None
patent: 88/10120 (1988-12-01), None
patent: 92/06117 (1992-04-01), None
patent: 94/25060 (1993-04-01), None
patent: WO 94/00148 (1994-01-01), None
patent: 95/26365 (1995-10-01), None
patent: 97/19698 (1995-11-01), None
Daniel et al., PNAS vol. 93 pp. 956-960, 1996.
Wraith et al. Cell. vol. 59:247-255, 1989.
Tisch et al. PNAS vol. 91:437-438, 1994.
Karin et al. J. Exp Med. vol. 180:2227-2237, 1994.
Kurup et al. Peptides, vol. 17. 183-190, 1996, 1996.
Norman, P. S. et al. Amer. J. Respir. Crit. Care Med. 154 (6 Pt 1):1623-1628, Dec. 1996.
Moiola, L. et al. J. Immunol. 152 (9): 4686-4698, May 1994.
Hetzel, C. et al. Int. Arch. Allergy Immunol. 107 (1-3): 275-277, May-Jun. 1995.
Protti, M.P., et al., “Myasthenia Gravis: Recognition of a Human Autoantigen at the Molecular Level”,Immunol. Today, 14, pp. 363-368, (1993).
Higgins, J.A., et al., “Peptide-induced nonresponsiveness of HLA-DP restricted human T cells reactive with Dermatophagoides spp. (house dust mite)”,The Journal of Allergy and Clinical Immunology, 90(5), pp. 749-756, (Nov. 1992).
Briner, T.J., et al., “Peripheral T-cell Tolerance Induced in Naive and Primed Mice by Subcutaneous Injection of Peptides from the Major Cat Allergen Fel d I”,Proc. Natl. Acad. Sci. USA, 90, 7608-7612 (1993).
Conti-Fine, B.M., “T-Cell Recognition of the Acetylcholine Receptor in Myasthenia Gravis”,IXthInternational Conference on Myasthenia Gravis and Related Disorders, Santa Monica, California, Abstract (May 7-10, 1997).
Counsell, C.M., et al., “Allergens, IgE, Mediators, Inflammatory Mechanisms. Definition of the Human T-Cell Epitopes of Fel d 1, the Major Allergen of the Domestic Cat”,J. Allergy Clin. Immunol., 98(5), 884-894 (1996).
Good, M.F., et al., “Peptide Immunization Can Elicit Malaria Protein-Specific Memory Helper but Not Proliferative T Cells”,Peptide Research, 3(3), 110-115 (1990).
Hoyne, G.F., et al., “Inhibition of T Cell and Antibody response to House Dust Mite Allergen by Inhalation of the Dominant T Cell Epitope in Naive and Sensitized Mice”,J. Exp. Med., 178, 1783-1788 (1993).
Lennon, V.A., et al., “Definition of Myasthenogenic Sites of the Human Acetylcholine Receptor Using Synthetic Peptides”,Annals of the New York Academy of Sciences, 505, 439-450 (1987).
Lennon, V.A., et al., “Region of Peptide 125-147 of Acetylcholine Receptor α Subunit is Exposed at Neuromuscular Junction and Induces Experimental Autoimmune Myasthenia Gravis, T-cell Immunity, and Modulating Antibodies”,Proc. Natl. Acad. Sci. USA, 82, 8805-8809 (1985).
Shaw, D.M., et al., “Influence of the T-Helper Epitope on the Titre and Affinity of Antibodies to B-Cell Epitopes after Co-Immunization”,Molecular Immunology, 30(11), 961-968 (1993).
Bellone, M., et al., “Experimental Myasthenia Gravis in Congenic Mice. Sequence Mapping and H-2 Restriction of T Helper Epitopes of the α Subunits ofTorpedo californicaand Murine Acetylcholine Receptors”,Eur. J. Immunol., 21, 2303-2310 (1991).
Conti-Fine, B.M., et al., In:Myasthenia Gravis: The Immunobiology of an Autoimmune Disease, R.G. Landers Co., Austin, TX, p. 89-104, 121-147, 149-206 (1997).
Conti-Fine, B.M., et al., “Antibodies as Tools to Study the Structure of Membrane Proteins: The Case of the Nicotinic Acetylcholine Receptor”,Annual Review of Biophysics and Biomolecular Structure, 25, 197-229 (1996).
Karpati, G., et al., “The Scope of Gene Therapy in Humans: Scientific, Safety and Ethical Considerations”,Neuromuscular Disorders, 7, 273-276 (1997).
Karpus, W.J., et al., “Inhibition of Relapsing Experimental Autoimmune Encephalomyelitis in SJL Mice by Feeding the Immunodominant PLP139-151 Peptide”,Journal of Neuroscience Research, 45, 410-423 (1996).
Lider, O., et al., “Suppression of Experimental Autoimmune Encephalomyelitis by Oral Adminstration of Myelin Basic Protein. II. Supression of Disease and in Vivo Immune Responses Is Mediated by Antigen-Specific CD8+T Lymphocytes”,The Journal of Immunology, 142, 748-752 (Feb. 1, 1989).
Ma, C.-G., et al., “Suppression of Experimental Autoimmune Myasthenia Gravis by Nasal Adminstration of Acetylcholine Receptor”,Journal of Neuroimmunology, 58, 51-60 (1995).
Metzler, B., et al., “Inhibition of Experimental Autoimmune Encephalomyelitis by Inhilation but not Oral Adminstration of the Encephalitogenic Peptide: Influence of MHC Binding Affinity”,International Immunology, 5, 1159-1165 (1993).
Neutra, M.R., et al., “Antigen Sampling Across Epithelial Barriers and Induction of Mucosal Immune Responses”,Annual Review of Immunology, 14, 275-300 (1996).
O'Sullivan, D., et al., “Characterization of the Specificity of Peptide Binding to Four DR Haplotypes”,The Journal of Immunology, 145, 1799-1808 (Sep. 15, 1990).
Phillips, G., et al., “American Society for Blood and Marrow Transplantation Guidelines for Clinical Centers”,Biology of Blood and Marrow Transplantations, 1, 54-55 (1995).
Schwartz, R.S., et al., “Autoimmunity and Autoimmune Diseases”, In:Fundamental Immunology, Second Edition, Paul, W.E., (ed.), Raven Press, New York, 819-859 (1989).
Wang, Z.-Y., et al., “Th1 Epitope Repertoire on the α Subunit of Human Muscle Acetylcholine Receptor in Myasthena Gravis”,Neurology, 48, 1643-1653 (1997).
Weiner, H.L., et al., “Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens”,Annual Review of Immunology, 12, 809-837 (1994).
Yu, M., et al., “A Predictable Sequential Determinant Spreading Cascade Invarible Accompanies Progression of Experimental Autoimmune Encephalomyelitis: A Basis for Peptide-Specific Therapy After Onset of Clinical Disease”,J. Exp. Med, 183, 1777-1788 (Apr. 1996).
Shenoy, M., et al., “Suppression of Experimental Autoimmune Myasthenia Gravis by Epitope-Specific Neonatal Tolerance to Synthetic Region α146-162 of Acetylcholine Receptor”,Clinical Immunology and Immunopathology, 66, 230-238 (Mar. 1993).
Shenoy, M., et al., “The Pathogenic Role of Acetylcholine Receptor α Chain Epitope within α146-162 in the Development of Experimental Autoimmune Myasthenia Gravis in C57BL6 Mice”,Clinical Immunology and Immunopathology, 73, 338-343 (Dec. 1994).
Yeh, T.-M., et al., “T Cells Reactive with a Small Synthetic Peptide of the Acetylcholine Receptor Can Provide Help for a Clonotypically Heterogeneous Antibody Response and Subsequently Impaired Muscle Function&#
Nolan Patrick J.
Regents of the University of Minnesota
LandOfFree
Methods to treat undesirable immune responses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to treat undesirable immune responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to treat undesirable immune responses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3518349